Compare Biocon with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs FRESENIUS KABI ONCO. - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON FRESENIUS KABI ONCO. BIOCON /
FRESENIUS KABI ONCO.
 
P/E (TTM) x 31.4 22.1 141.8% View Chart
P/BV x 3.7 3.1 120.1% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 BIOCON    FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    BIOCON
Mar-19
FRESENIUS KABI ONCO.
Mar-13
BIOCON /
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs707176 401.9%   
Low Rs55479 705.5%   
Sales per share (Unadj.) Rs91.937.7 243.9%  
Earnings per share (Unadj.) Rs16.75.1 328.1%  
Cash flow per share (Unadj.) Rs24.26.7 359.6%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs101.642.5 238.9%  
Shares outstanding (eoy) m600.00158.23 379.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.93.4 203.2%   
Avg P/E ratio x37.725.0 151.0%  
P/CF ratio (eoy) x26.118.9 137.8%  
Price / Book Value ratio x6.23.0 207.4%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m378,33020,135 1,879.0%   
No. of employees `0006.11.2 532.2%   
Total wages/salary Rs m11,653703 1,657.1%   
Avg. sales/employee Rs Th8,994.35,176.2 173.8%   
Avg. wages/employee Rs Th1,900.7610.4 311.4%   
Avg. net profit/employee Rs Th1,635.3699.6 233.8%   
INCOME DATA
Net Sales Rs m55,1445,963 924.8%  
Other income Rs m1,44418 8,022.2%   
Total revenues Rs m56,5885,981 946.1%   
Gross profit Rs m15,8831,430 1,110.6%  
Depreciation Rs m4,478258 1,736.3%   
Interest Rs m709-26 -2,726.9%   
Profit before tax Rs m12,1401,216 998.2%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m2,123342 620.4%   
Profit after tax Rs m10,026806 1,244.1%  
Gross profit margin %28.824.0 120.1%  
Effective tax rate %17.528.1 62.2%   
Net profit margin %18.213.5 134.5%  
BALANCE SHEET DATA
Current assets Rs m48,2285,102 945.4%   
Current liabilities Rs m30,3762,385 1,273.4%   
Net working cap to sales %32.445.6 71.1%  
Current ratio x1.62.1 74.2%  
Inventory Days Days68150 45.5%  
Debtors Days Days86113 75.5%  
Net fixed assets Rs m64,1305,148 1,245.7%   
Share capital Rs m3,000158 1,896.3%   
"Free" reserves Rs m57,9806,556 884.4%   
Net worth Rs m60,9806,732 905.8%   
Long term debt Rs m15,766952 1,655.7%   
Total assets Rs m121,92410,388 1,173.7%  
Interest coverage x18.1-45.8 -39.6%   
Debt to equity ratio x0.30.1 182.8%  
Sales to assets ratio x0.50.6 78.8%   
Return on assets %8.87.5 117.3%  
Return on equity %16.412.0 137.3%  
Return on capital %16.814.6 114.7%  
Exports to sales %28.174.5 37.8%   
Imports to sales %18.924.8 76.1%   
Exports (fob) Rs m15,5064,441 349.2%   
Imports (cif) Rs m10,3991,477 703.9%   
Fx inflow Rs m15,5065,298 292.7%   
Fx outflow Rs m10,3991,772 586.8%   
Net fx Rs m5,1073,525 144.9%   
CASH FLOW
From Operations Rs m11,5461,274 906.2%  
From Investments Rs m-7,138-1,204 592.8%  
From Financial Activity Rs m-2,417-196 1,232.5%  
Net Cashflow Rs m2,103-126 -1,665.1%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 81.0 25.4%  
Indian inst/Mut Fund % 8.4 0.3 2,800.0%  
FIIs % 10.7 9.6 111.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 9.1 218.7%  
Shareholders   109,995 42,599 258.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   NOVARTIS  TORRENT PHARMA  DISHMAN PHARMA  CIPLA  ABBOTT INDIA  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 500 Points Lower; Dow Futures Down by 77 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 553 points, down 1.1% at 47,794 levels.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 27, 2021 01:22 PM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS